CN106795161B - 作为因子xia抑制剂的嘧啶酮 - Google Patents
作为因子xia抑制剂的嘧啶酮 Download PDFInfo
- Publication number
- CN106795161B CN106795161B CN201580053079.7A CN201580053079A CN106795161B CN 106795161 B CN106795161 B CN 106795161B CN 201580053079 A CN201580053079 A CN 201580053079A CN 106795161 B CN106795161 B CN 106795161B
- Authority
- CN
- China
- Prior art keywords
- base
- compound
- methyl
- butyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210580097.2A CN114957255A (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
| CN201910882473.1A CN110734435B (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462058316P | 2014-10-01 | 2014-10-01 | |
| US62/058,316 | 2014-10-01 | ||
| PCT/US2015/042576 WO2016053455A1 (en) | 2014-10-01 | 2015-07-29 | Pyrimidinones as factor xia inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910882473.1A Division CN110734435B (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
| CN202210580097.2A Division CN114957255A (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106795161A CN106795161A (zh) | 2017-05-31 |
| CN106795161B true CN106795161B (zh) | 2019-10-15 |
Family
ID=53784023
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210580097.2A Pending CN114957255A (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
| CN201910882473.1A Active CN110734435B (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
| CN201580053079.7A Active CN106795161B (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210580097.2A Pending CN114957255A (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
| CN201910882473.1A Active CN110734435B (zh) | 2014-10-01 | 2015-07-29 | 作为因子xia抑制剂的嘧啶酮 |
Country Status (34)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| NO2760821T3 (US07585860-20090908-C00093.png) | 2014-01-31 | 2018-03-10 | ||
| TWI688564B (zh) * | 2014-01-31 | 2020-03-21 | 美商必治妥美雅史谷比公司 | 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物 |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| NO2721243T3 (US07585860-20090908-C00093.png) * | 2014-10-01 | 2018-10-20 | ||
| SG11201702628XA (en) | 2014-10-01 | 2017-04-27 | Merck Patent Gmbh | Boronic acid derivatives |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| WO2016205482A1 (en) | 2015-06-19 | 2016-12-22 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
| EP3328852B1 (en) | 2015-07-29 | 2021-04-28 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group |
| JP6629958B2 (ja) * | 2015-07-29 | 2020-01-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤 |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US10752641B2 (en) | 2016-03-02 | 2020-08-25 | Bristol-Myers Squibb Company | Diamide macrocycles having factor XIa inhibiting activity |
| EP3436436B1 (en) | 2016-03-31 | 2022-05-11 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| JP6888021B2 (ja) | 2016-03-31 | 2021-06-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | デングウイルス複製阻害剤としての置換インドール誘導体 |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CR20180494A (es) | 2016-04-01 | 2019-01-29 | Janssen Pharmaceuticals Inc | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue |
| CN110062757B (zh) * | 2017-01-18 | 2022-03-04 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| KR102625988B1 (ko) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체 |
| TW202104228A (zh) * | 2019-04-11 | 2021-02-01 | 美商必治妥美雅史谷比公司 | 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物 |
| CA3132365A1 (en) * | 2019-04-11 | 2020-10-15 | Nicolas Cuniere | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7 8,9,10-hexahydro-11,15-(metheno)pyrazolo [4,3-b][1,7]diazacyclotetradecin-5(6h)-one |
| AU2020257911B2 (en) * | 2019-04-16 | 2023-01-05 | China Resources Biopharmaceutical Company Limited | Macrocyclic derivatives acting as XIa factor inhibitor |
| WO2021013209A1 (zh) * | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| EP4132930A1 (en) * | 2020-04-10 | 2023-02-15 | Bristol-Myers Squibb Company | Crystalline forms of (9, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.0] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one |
| TW202229280A (zh) * | 2020-10-12 | 2022-08-01 | 美商必治妥美雅史谷比公司 | （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法 |
| TW202246268A (zh) * | 2021-04-21 | 2022-12-01 | 大陸商上海美悦生物科技發展有限公司 | FXIa抑制劑及其藥物組合物、製備方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| AU5546000A (en) | 1999-06-14 | 2001-01-02 | Protherics Molecular Design Limited | Compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| ATE544750T1 (de) | 2001-09-21 | 2012-02-15 | Bristol Myers Squibb Co | Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| WO2011100401A1 (en) * | 2010-02-11 | 2011-08-18 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
| TW201311689A (zh) * | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| US9327839B2 (en) | 2011-08-05 | 2016-05-03 | General Atomics | Method and apparatus for inhibiting formation of and/or removing ice from aircraft components |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| AU2012356374B2 (en) * | 2011-12-21 | 2017-06-22 | Ono Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| SG11201500271UA (en) * | 2012-08-03 | 2015-03-30 | Bristol Myers Squibb Co | Dihydropyridone p1 as factor xia inhibitors |
| PT2882734T (pt) * | 2012-08-03 | 2016-12-09 | Bristol Myers Squibb Co | Di-hidropiridona pi como inibidores do fator xia |
| NO2760821T3 (US07585860-20090908-C00093.png) * | 2014-01-31 | 2018-03-10 | ||
| TWI688564B (zh) * | 2014-01-31 | 2020-03-21 | 美商必治妥美雅史谷比公司 | 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物 |
| NO2721243T3 (US07585860-20090908-C00093.png) * | 2014-10-01 | 2018-10-20 |
-
2012
- 2012-06-14 NO NO12801069A patent/NO2721243T3/no unknown
-
2015
- 2015-07-29 EP EP15747721.7A patent/EP3089979B1/en active Active
- 2015-07-29 EP EP17189935.4A patent/EP3293186B1/en active Active
- 2015-07-29 NZ NZ731416A patent/NZ731416A/en unknown
- 2015-07-29 KR KR1020187033199A patent/KR102269999B1/ko active IP Right Grant
- 2015-07-29 MA MA40123A patent/MA40123A1/fr unknown
- 2015-07-29 PE PE2020001966A patent/PE20210922A1/es unknown
- 2015-07-29 LT LTEP17189935.4T patent/LT3293186T/lt unknown
- 2015-07-29 DK DK15747721.7T patent/DK3089979T3/en active
- 2015-07-29 TW TW104124664A patent/TWI692478B/zh active
- 2015-07-29 TN TN2017000112A patent/TN2017000112A1/en unknown
- 2015-07-29 DK DK17189935.4T patent/DK3293186T3/da active
- 2015-07-29 AR ARP150102426A patent/AR101367A1/es unknown
- 2015-07-29 PT PT157477217T patent/PT3089979T/pt unknown
- 2015-07-29 CN CN202210580097.2A patent/CN114957255A/zh active Pending
- 2015-07-29 MY MYPI2017701150A patent/MY183987A/en unknown
- 2015-07-29 ES ES15747721.7T patent/ES2655884T3/es active Active
- 2015-07-29 HU HUE17189935A patent/HUE052812T2/hu unknown
- 2015-07-29 EP EP23185426.6A patent/EP4286372A3/en active Pending
- 2015-07-29 PE PE2017000527A patent/PE20170939A1/es unknown
- 2015-07-29 EP EP20197284.1A patent/EP3828186B1/en active Active
- 2015-07-29 RS RS20201472A patent/RS61183B1/sr unknown
- 2015-07-29 PL PL15747721T patent/PL3089979T3/pl unknown
- 2015-07-29 CN CN201910882473.1A patent/CN110734435B/zh active Active
- 2015-07-29 HU HUE15747721A patent/HUE038061T2/hu unknown
- 2015-07-29 PT PT171899354T patent/PT3293186T/pt unknown
- 2015-07-29 ES ES20197284T patent/ES2963267T3/es active Active
- 2015-07-29 ES ES17189935T patent/ES2836270T3/es active Active
- 2015-07-29 LT LTEP15747721.7T patent/LT3089979T/lt unknown
- 2015-07-29 CA CA2963395A patent/CA2963395C/en active Active
- 2015-07-29 WO PCT/US2015/042576 patent/WO2016053455A1/en active Application Filing
- 2015-07-29 SG SG10201911652TA patent/SG10201911652TA/en unknown
- 2015-07-29 TN TNP/2018/000229A patent/TN2018000229A1/en unknown
- 2015-07-29 EA EA201790595A patent/EA031590B1/ru not_active IP Right Cessation
- 2015-07-29 CN CN201580053079.7A patent/CN106795161B/zh active Active
- 2015-07-29 JP JP2017517766A patent/JP6462865B2/ja active Active
- 2015-07-29 KR KR1020177011233A patent/KR101921436B1/ko active IP Right Grant
- 2015-07-29 TW TW109111475A patent/TWI769442B/zh active
- 2015-07-29 NZ NZ766570A patent/NZ766570A/en unknown
- 2015-07-29 RS RS20180046A patent/RS56786B1/sr unknown
- 2015-07-29 AU AU2015324530A patent/AU2015324530B2/en active Active
- 2015-07-29 UY UY0001036244A patent/UY36244A/es active IP Right Grant
- 2015-07-29 SI SI201531423T patent/SI3293186T1/sl unknown
- 2015-07-29 SG SG11201702576QA patent/SG11201702576QA/en unknown
- 2015-07-29 MX MX2017003695A patent/MX2017003695A/es active IP Right Grant
- 2015-07-29 SI SI201530123T patent/SI3089979T1/sl unknown
-
2017
- 2017-03-21 MX MX2020010840A patent/MX2020010840A/es unknown
- 2017-03-24 CL CL2017000712A patent/CL2017000712A1/es unknown
- 2017-03-28 IL IL251434A patent/IL251434B/en active IP Right Grant
- 2017-03-29 PH PH12017500580A patent/PH12017500580A1/en unknown
- 2017-04-07 ZA ZA2017/02478A patent/ZA201702478B/en unknown
- 2017-04-20 CO CONC2017/0003833A patent/CO2017003833A2/es unknown
- 2017-12-15 CY CY20171101314T patent/CY1119678T1/el unknown
- 2017-12-18 HR HRP20171950TT patent/HRP20171950T1/hr unknown
-
2018
- 2018-12-27 JP JP2018244086A patent/JP6937734B2/ja active Active
-
2020
- 2020-01-20 AU AU2020200376A patent/AU2020200376B2/en active Active
- 2020-01-27 PH PH12020500195A patent/PH12020500195A1/en unknown
- 2020-08-03 IL IL276470A patent/IL276470B/en active IP Right Grant
- 2020-12-03 HR HRP20201927TT patent/HRP20201927T1/hr unknown
- 2020-12-04 CY CY20201101149T patent/CY1123663T1/el unknown
-
2021
- 2021-08-31 JP JP2021140618A patent/JP7317905B2/ja active Active
- 2021-10-05 AU AU2021245098A patent/AU2021245098B2/en active Active
-
2023
- 2023-07-19 JP JP2023117409A patent/JP2023134734A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106795161B (zh) | 作为因子xia抑制剂的嘧啶酮 | |
| CA2937739C (en) | Macrocycles with heterocyclic p2' groups as factor xia inhibitors | |
| CN106459051B (zh) | 含杂环基团的大环fxia抑制剂 | |
| CN105228996B (zh) | 作为因子XIa抑制剂的含取代唑类的四氢异喹啉 | |
| TW201410667A (zh) | 二氫吡啶酮ｐ１作爲凝血因子ｘｉａ抑制劑 | |
| CN108026083B (zh) | 作为因子xia抑制剂的二酰胺大环 | |
| KR102086934B1 (ko) | 알킬 또는 시클로알킬 P2' 모이어티를 갖는 인자 XIa 마크로시클릭 억제제 | |
| CN107074821A (zh) | 作为fxia抑制剂的二胺大环化合物 | |
| CN107922393A (zh) | 携带非芳族p2,基团的因子xia新大环 | |
| TWI834182B (zh) | 作為因子xia抑制劑之嘧啶酮 | |
| CN104520289B (zh) | 作为凝血因子xia抑制剂的二氢吡啶酮p1 | |
| BR112017006702B1 (pt) | Pirimidinonas inibidoras de fator xia, composição farmacêutica e seu uso | |
| CN104520289A (zh) | 作为凝血因子xia抑制剂的二氢吡啶酮p1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |